​

Monopar Therapeutics (MNPR) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

MNPR Stock Forecast

Monopar Therapeutics stock forecast is as follows: an average price target of $29.50 (represents a -23.97% downside from MNPR’s last price of $38.80) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

MNPR Price Target

The average price target for Monopar Therapeutics (MNPR) is $29.50 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $37.00 to $22.00. This represents a potential -23.97% downside from MNPR's last price of $38.80.

MNPR Analyst Ratings

Buy

According to 4 Wall Street analysts, Monopar Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for MNPR stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Monopar Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 19, 2024Justin WalshUBS$37.00$19.0194.63%-4.64%
Nov 11, 2024Sean LeeH.C. Wainwright$22.00$15.8139.15%-43.30%

The latest Monopar Therapeutics stock forecast, released on Nov 19, 2024 by Justin Walsh from UBS, set a price target of $37.00, which represents a 94.63% increase from the stock price at the time of the forecast ($19.01), and a -4.64% decrease from MNPR last price ($38.80).

Monopar Therapeutics Price Target by Period

1M3M12M
# Anlaysts-22
Avg Price Target-$29.50$29.50
Last Closing Price$38.80$38.80$38.80
Upside/Downside-100.00%-23.97%-23.97%

In the current month, the average price target of Monopar Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Monopar Therapeutics's last price of $38.80. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Jan 10, 2025Piper SandlerOverweightInitialise
Oct 11, 2024Rodman & RenshawBuyInitialise
Aug 12, 2024H.C. WainwrightBuyBuyHold
Jan 28, 2021Roth CapitalBuyInitialise

Monopar Therapeutics's last stock rating was published by Piper Sandler on Jan 10, 2025. The company Initialise its MNPR rating from "null" to "Overweight".

Monopar Therapeutics Financial Forecast

Monopar Therapeutics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
# Analysts-------
Surprise %-------

Monopar Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. MNPR's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Monopar Therapeutics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EBITDA-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

undefined analysts predict MNPR's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Monopar Therapeutics's previous annual EBITDA (undefined) of $NaN.

Monopar Therapeutics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
Net Income-------
Avg Forecast$-26.26M$-23.66M$-19.22M$-15.70M$-12.11M$-35.03M$-1.75M
High Forecast$-26.26M$-23.66M$-19.22M$-9.64M$-10.97M$-35.03M$-1.75M
Low Forecast$-26.26M$-23.66M$-19.22M$-21.49M$-12.87M$-35.03M$-1.75M
Surprise %-------

Monopar Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. MNPR's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Monopar Therapeutics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
SG&A-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

Monopar Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to MNPR last annual SG&A of $NaN (undefined).

Monopar Therapeutics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EPS-------
Avg Forecast$-0.75$-0.67$-0.55$-0.45$-0.34$-0.99$-0.50
High Forecast$-0.75$-0.67$-0.55$-0.27$-0.31$-0.99$-0.50
Low Forecast$-0.75$-0.67$-0.55$-0.61$-0.37$-0.99$-0.50
Surprise %-------

According to undefined Wall Street analysts, Monopar Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to MNPR previous annual EPS of $NaN (undefined).

Monopar Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
PEPGPepGen$1.84$29.501503.26%Buy
ANTXAN2 Therapeutics$1.18$8.75641.53%Buy
MOLNMolecular Partners$5.22$29.00455.56%Buy
AVTEAerovate Therapeutics$2.58$13.00403.88%Hold
PMVPPMV Pharmaceuticals$1.43$6.00319.58%Buy
ACRVAcrivon Therapeutics$5.55$22.50305.41%Buy
SCPHscPharmaceuticals$3.29$13.00295.14%Buy
ANEBAnebulo Pharmaceuticals$1.54$6.00289.61%Buy
MLYSMineralys Therapeutics$10.36$30.00189.58%Buy
ADAGAdagene$1.85$5.00170.27%Buy
PHVSPharvaris$17.64$42.00138.10%Buy
DMACDiaMedica Therapeutics$5.89$8.5044.31%Buy
RZLTRezolute$5.06$6.6731.82%Buy
MNPRMonopar Therapeutics$38.80$29.50-23.97%Buy

MNPR Forecast FAQ

Is Monopar Therapeutics a good buy?

Yes, according to 4 Wall Street analysts, Monopar Therapeutics (MNPR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of MNPR's total ratings.

What is MNPR's price target?

Monopar Therapeutics (MNPR) average price target is $29.5 with a range of $22 to $37, implying a -23.97% from its last price of $38.8. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Monopar Therapeutics stock go up soon?

According to Wall Street analysts' prediction for MNPR stock, the company can go down by -23.97% (from the last price of $38.8 to the average price target of $29.5), down by -4.64% based on the highest stock price target, and down by -43.30% based on the lowest stock price target.

Can Monopar Therapeutics stock reach $60?

MNPR's average twelve months analyst stock price target of $29.5 does not support the claim that Monopar Therapeutics can reach $60 in the near future.

What are Monopar Therapeutics's analysts' financial forecasts?

Monopar Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-48.89M (high $-47.754M, low $-49.646M), average SG&A $0 (high $0, low $0), and average EPS is $-1.839 (high $-1.807, low $-1.861). MNPR's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-84.842M (high $-78.782M, low $-90.626M), average SG&A $0 (high $0, low $0), and average EPS is $-2.41 (high $-2.238, low $-2.574).